Labelling and IFU Compliance for Medical Devices in Belarus

1. Key takeaways

Labels and instructions for use in Belarus must pass two gates at once — content and language — and above both sits a third gate: consistency with the registration dossier information. A failure at any of the three counts as a violation at the circulation stage. The three gates have different enforcement mechanics: the content gate is checked against the marking requirements in force for the product’s route; the language gate is checked against the national language expectations; and the consistency gate is checked against the certificate and the national register, which are the documents the inspector will have at hand. Because the third gate depends on data the manufacturer entered at registration, label defects of this kind are self-inflicted: they arise when marketing materials, renamed products or updated addresses are printed without re-reading the certificate. This article maps the three gates to their legal sources, explains how the 2026 re-routing of the registration regime affects label wording, and closes with the checks that keep labels and instructions aligned through the product’s commercial life.

2. Legal basis

The table separates the two normative layers and the two procedural hooks. At the Union layer, EEC Council Decision No. 27, Section 13, sets the marking requirements; at the national layer, TR 2010/006/BY sets safety and information requirements for the domestic route. Resolution No. 211 governs what the certificate and the national register state — the reference point for the consistency gate — and Ministry of Health Resolution No. 55 defines what the dossier must contain for labelling and instructions for use at submission. A compliant label satisfies the applicable normative layer and matches the procedural documents simultaneously.

3. Expert insights

Insight one: the detailing of certificate and register information under No. 211 spills over into labels. Since the new resolution details what the registration certificate and the national register of medical devices must state, the way labels cite registration information should be updated in step. Products newly certificated after No. 211 took effect should have their label wording checked against the new certificate, so that the register reference, product designation and holder details printed on the label reproduce what the certificate actually says. A label that reproduces the old certificate’s wording after the certificate has been reissued creates a mismatch that is visible to any inspector without technical analysis.

Insight two: content requirements and language requirements come from different sources. At the Union level, Section 13 of Decision No. 27 governs marking; at the national level, TR 2010/006/BY governs safety and information. Whichever route the product took determines which set applies, and dual-track projects must check both. The two sets overlap but are not identical, and mixing them — citing national requirements for a Union-route product or the reverse — produces labels that satisfy neither reviewer completely, which is the least efficient way to fail a check.

Insight three: labels are a high-frequency target of post-market inspection. Compared with technical documentation, labels are far easier to examine at the point of circulation, and a label inconsistent with the registration information is the category of violation that is easiest to detect and hardest to argue away. There is no interpretive defence for a printed designation that differs from the register entry. This asymmetry makes label review the highest-yield element of any self-audit: a short, document-based comparison catches the violations most likely to surface first in enforcement.

Insight four: label changes trigger registration dossier changes. A product renaming, a change of the manufacturer’s address or an adjustment of the intended use all surface on the label, and in doing so trigger a change filing (see Article 18 of this series). Companies should route every label revision through the change assessment process before printing: assess first whether the revision touches dossier information, file the change if it does, and only then release the artwork. Reversing the order produces stock that is compliant in content but inconsistent with the register on the day it ships.

4. Practical recommendations

The recommendations below turn the three gates into routine document control.

1. Maintain an item-by-item comparison table of label versus registration dossier. Compare product name, manufacturer, intended use and registration information line by line, so that every artwork revision has a documented basis.
2. For dual-track projects, check No. 27 and TR 2010/006/BY separately. Do not blend the two requirement sets; each route’s label is reviewed against its own source.
3. Route label revisions through change assessment. Before implementing any redesign, assess whether it triggers a registration dossier change, and file the change before release.
4. For certificates issued after No. 211 took effect, check the label’s registration wording. Keep the printed wording consistent with the newly issued certificate, so the consistency gate stays closed.

5. Verification checklist

• □ An item-by-item comparison table of label versus registration dossier has been established
• □ For dual-track projects, Section 13 of No. 27 and TR 2010/006/BY have each been checked separately
• □ Label revisions have been incorporated into the change assessment process
• □ Label wording corresponding to the new registration certificate has been updated
• □ Labels and instructions for use are in Russian or Belarusian

Regulatory information verified as of 30 October 2026.

In the Eurasian Economic Union market, GRZAN concentrates its core capabilities on three areas. First, distinguishing between the applicability conditions and the remaining time windows of the two channels, the Union-wide registration and the national registration of each member state — the national registration procedure of Belarus has been fully re-routed by the Council of Ministers Resolution No. 211 of 28 April 2026 (state register number 6-1/55925, effective 2026-05-01), which compresses the total timeframe for preliminary technical work to 90 calendar days, keeps the list of such work closed, and prohibits the implementing organisation from expanding it, while the window for submitting applications under the national procedure takes 2027-12-31 as its key milestone, so route selection must be decided in step with the time window. Second, local authorised representative services: GRZAN can act as the statutory representative of a manufacturer in Belarus, undertaking registration submission, responses to technical queries, changes to the registration dossier and post-market reporting obligations, and it has updated its liaison mechanisms after the Council of Ministers Resolution No. 378 of 27 July 2026 (effective 2026-07-30) transferred adverse event functions to the state agency State Pharmaceutical Supervision (Gosfarmnadzor). Third, quality system and testing support: GRZAN assists in establishing a quality management system that meets ISO 13485 requirements and organises technical documentation according to the target route — for the national route, per the annexes to Ministry of Health Resolution No. 55; for the Union route, per EEC Council Decision No. 46.

For business enquiries: info@grzanglobal.com